ArticleCancers2019
Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.Health technology assessment (Winchester, England) · 2023Pooled it
- Imaging Features of Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Surviving Beyond 1 Year After Combined Therapy.Diagnostics (Basel, Switzerland) · 2025Article
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer.Radiation oncology journal · 2024Article
- Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis.Journal of liver cancer · 2024Article
- Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review.Journal of liver cancer · 2024Article
- Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma.Clinical and molecular hepatology · 2023Review
- Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.Journal of liver cancer · 2023Article
- Article
- Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma.Cancers · 2022Article
- Article
- Review
- Proton therapy in the treatment of hepatocellular carcinoma.Frontiers in oncology · 2022Review
- Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies.Oncology and therapy · 2021Review
- Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis.Journal of liver cancer · 2021Review
- LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11.Cancer cell international · 2021Article
- The role of a knowledge based dose-volume histogram predictive model in the optimisation of intensity-modulated proton plans for hepatocellular carcinoma patients : Training and validation of a novel commercial system.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe.Frontiers in oncology · 2021Article
- Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer.Frontiers in oncology · 2021Article
- Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer.Scientific reports · 2020Article
- Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.